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Abstract
Introduction: While multiple myeloma (MM) is a rare diagnosis within primary care, its precursor MGUS
(monoclonal gammopathy of undetermined significance) is more common, particularly among older populations.
Upon first detection, the majority of MGUS patients will be under the care of their General Practitioner (GP)/Family
Doctor who is also often the first healthcare professional that patients report symptoms of progression to. However,
our previous work with MGUS patients and haematology healthcare professionals has suggested that knowledge
and awareness of MGUS is low among GPs.
Methods: An online survey was undertaken to investigate knowledge and awareness of MGUS and services
needed by GPs/GP trainees to support these patients. The survey was promoted at a large European primary care
conference and via social media. Descriptive statistics were utilised to compare participant responses.
Results: In total 58 GPs (n = 35 GPs and n = 23 GP trainees) from 24 countries responded. Overall, self-reported
familiarity with the term MGUS was low (mean score: 2.21/5, standard deviation (SD): 1.09), but higher among GPs
who reported having at least one MGUS patient (mean score: 2.83/5, SD 0.99). The majority (88.2%) of GPs/GP
trainees stated they would feel uncomfortable discussing MGUS with patients. The increased risk of haematological
malignancies was identified by 62.1% of GPs/GP trainees with MM, lymphoma and myelodysplastic syndromes the
most commonly reported cancers associated with MGUS. The majority (81.6%) of GPs/GP trainees were supportive
of patient follow-up via telephone clinics (phlebotomy performed in GP practice with patient management
maintained by haematology) but only 27.1% stated they would be happy to solely manage all low/low-
intermediate risk MGUS patients. A laboratory report alerting to the possibility of MGUS or a haematological
malignancy was reported as the most useful service which could be implemented to help GPs manage MGUS
patients. The need for MGUS focused information and education resources for GPs was also highlighted.
Conclusions: The findings of this study highlight a lack of knowledge and awareness of MGUS among GPs/ GP
trainees. The majority of GPs/GP trainees are happy to support haematology in managing these patients but require
assistance and support in providing these services.
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Background
Multiple myeloma (MM), an incurable B-cell malignancy
[1] is the third most common haematological malignancy
diagnosed worldwide [2]. MM is proceeded by monoclonal
gammopathy of undetermined significance (MGUS) [3, 4],
which is estimated to be present in 3.2% of the population
aged 50 years and older [5]. Owing to its asymptomatic
nature, MGUS is markedly under diagnosed and is often
detected incidentally upon routine blood testing [6, 7].
Clinically, MGUS is defined, by the International Myeloma
Working Group, as < 30 g/l of serum monoclonal (M) pro-
tein, < 10% plasma cell infiltration in the bone marrow and
absence of end organ damage (CRAB criteria – hypercal-
caemia, renal insufficiency, anaemia and bone lesions) [8].
The annual rate of progression to MM and related haem-
atological malignancies is between 0.5–1%, and remains
elevated beyond 25 years of observation [9, 10].
Follow-up guidelines for MGUS vary internationally,
however, most advocate for one annual follow-up visit
with relevant myeloma-related investigations [6, 11–
13]. In general, it is recommended that these follow-up
visits continue indefinitely or until life expectancy be-
comes limited [6, 11–13].
The majority of patients detected with an M-protein
will initially be under the care of their general practi-
tioner (GP)/Primary Care Physician or a clinician out-
side haematology [11]. Previous research by the study
team investigating the psychosocial impact of MGUS
among patients has highlighted low awareness and
knowledge of MGUS among healthcare professionals
outside haematology and in particular, among their GP
(Unpublished findings). In response to these findings,
the study team undertook a short survey of haematology
doctors and nurses attending the Haematology Associ-
ation of Ireland meeting in October 2016 [14]. Similar
findings to the patient study were reported, with haema-
tology healthcare professionals highlighting confusion
among patients and GPs alike [14]. Of note, many
haematology healthcare professionals reported a com-
bined approach to follow-up involving primary and sec-
ondary care is now needed to deal with the increasing
number of low/low-intermediate risk MGUS patients be-
ing diagnosed [14]. Respondents also recognised that
GPs should be supported in this role and provided with
guidelines to avoid over-diagnosing and over-referring
patients to haematology [14]. Within the current study,
we explored GP knowledge and awareness of MGUS
and their perceived support needs to manage MGUS
patients within primary care.
Methods
GPs/trainees attending the 22nd WONCA (World
Organisation of National Colleges, Academics and
Academic Associations of General Practitioners/Family
Physicians) Europe conference in Prague, Czech Republic
(http://www.woncaeurope2017.eu/) were invited to par-
ticipate in an online survey, detailed below. The WONCA
Europe Conference is an annual Europe-wide GP/family
doctor conference attended by GPs and GP trainees from
across the world.
Survey
In the absence of a validated questionnaire, a short on-
line survey was developed informed by the study team’s
previous studies with patients and haematology health-
care professionals. The survey was hosted on Survey-
Monkey®. The survey consisted of 35 questions
developed by the study team to capture information re-
lating to awareness and knowledge of MGUS and poten-
tial support needs of GPs/GPs in training. The first
seven questions were designed to capture respondent
demographics and the remaining questions related spe-
cifically to MGUS. Familiarity with MGUS was assessed
using a likert scale of 1–5 with 1 equivalent to ‘no know-
ledge/never heard of it’ and 5 being ‘very familiar’. Mul-
tiple choice questions and skip logic were used to
reduce the time taken to complete the survey (median
time for completion: 9 min). All respondents were re-
quired to answer the multiple choice/tick box questions
but could leave open-ended questions blank. All re-
sponses to the survey were anonymous. To increase
awareness of the survey, study posters, leaflets and pro-
motion slides were used to advertise the study during
the conference. The study team set up a twitter account
(@QUB_GPsurvey) and a promotion link was included
on the WONCA Europe website. Respondents were pro-
vided with the option of being included in a draw for a
Samsung Galaxy® tablet.
Data analysis
The returned survey responses were transferred directly
from SurveyMonkey® into Microsoft Excel to facilitate
data cleaning. The data was analysed to investigate GP
awareness and knowledge of MGUS and the support
services needed to manage this group of patients. We
excluded one respondent from the analysis who stated
in the survey that they were not a GP/GP trainee. De-
scriptive statistics and Chi-squared and Fisher’s Exact
tests were used to compare participant responses based
on variables of interest including GP status (registered GP
vs trainee), world region and number of MGUS patients
within practice. To assess awareness of MGUS, mean
scores and standard deviation were calculated based on a
self-reported scale ranging from 1 to 5 with 1 being ‘un-
familiar’ and 5 being ‘very familiar’ with MGUS. Missing
data was coded as a specific category and excluded from
the denominator when calculating responses to questions
asked. Responses to open-ended questions were reviewed
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and analysed using content analysis [15]. All tests were
two tailed and a p-value < 0.05 was considered statistically
significant. All analyses were performed using STATA
(version 14, StataCorp, TX, USA).
Ethical approval
This study received ethical approval from the School of
Medicine, Dentistry and Biomedical Sciences Research
Ethics Committee, Queen’s University Belfast (Ref 17.22).
Results
Overview of respondents
In total, 58 GPs/GP trainees from 24 countries responded
to the online survey, Table 1. Of the 58 respondents, the
majority were male (55.2%), practicing GP’s/Family Practi-
tioners (60.3%) and had completed their medical degree
within the last 5 years (43.1%). As expected, the major-
ity (n = 47; 81%) of respondents came from European
countries (Portugal n = 9, United Kingdom n = 6,
Netherlands n = 6, Spain n = 6, Ireland n = 4, Greece n = 3,
Croatia n = 3, Lithuania n = 2, Luxembourg n = 2, Serbia
n = 2, Romania n = 1, Finland n = 1, Sweden n = 1,
Switzerland n = 1). Six (10.3%) respondents came from
Asia (Hong Kong n = 1, Indonesia n = 1, Israel n = 1,
Lebanon n = 1, Saudi Arabia n = 1 and Turkey n = 1) while
three (5.2%) came from The Americas (n = 1 USA, n = 1
Brazil and n = 1 Mexico) and one from Africa (Tunisia).
The majority of respondents worked in metropolitan/
urban areas (72.4%) and served more than 1000 patients
(89.7%). Just over half of the respondents (n = 30; 51.7%)
reported knowing that they had at least one MGUS pa-
tient enrolled within their GP practice.
Table 1 GP/GP trainee respondent demographics
Total (n = 58) Registered GP (n = 35) GP trainee (n = 23) p-value*
Gender
Male 32 (55.2) 22 (62.9) 10 (43.5) 0.15
Female 26 (44.8) 13 (37.1) 13 (56.5)
Continent
Europe 47 (81) 27 (77.1) 20 (87) 0.54
The Americas 3 (5.2) 1 (2.9) 2 (8.7)
Asian 6 (10.3) 5 (14.3) 1 (4.4)
Africa 1 (1.7) 1 (2.9) 0
Missing 1 (1.7) 1 (2.9) 0
Years working as a GP or trainee since completing medical degree
0–5 years 25 (43.1) 5 (14.3) 20 (87) ≤0.001
6–10 years 13 (22.4) 11 (31.4) 2 (8.7)
11–20 years 13 (22.4) 13 (37.1) 0
20+ years 7 (12.1) 6 (17.1) 1 (4.4)
GP Practice
Metropolitan/urban 42 (72.4) 25 (71.4) 17 (73.9) 0.52
Rural 15 (25.9) 10 (28.6) 5 (21.7)
Prefer not to say/Not applicable 1 (1.7) 0 1 (4.4)
Number of patients within GP/Family practice
0–500 patients 3 (5.2) 1 (2.9) 2 (8.7) 0.83
501–1000 patients 3 (5.2) 2 (5.7) 1 (4.4)
1001–2000 patients 25 (43.1) 16 (45.7) 9 (39.1)
2001+ patients 27 (46.6) 16 (45.7) 11 (47.8)
Number of MGUS patients that have/are currently within GP/Family practice
None 8 (13.8) 5 (14.3) 3 (13) 0.19
1–10 patients 24 (41.4) 18 (51.4) 6 (26.1)
11–50 patients 5 (8.6) 2 (5.7) 3 (13)
51–100 patients 1 (1.7) 1 (2.9) 0
Don’t know/Prefer not to say/Not applicable 20 (34.5) 9 (25.7) 11 (47.8)
*Fisher’s exact test used to estimate p-value where cell count < 5
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Knowledge and awareness of MGUS
When asked to rank familiarity with the term MGUS on
a scale of 1–5 (with 1 being unfamiliar and 5 being very
familiar), the respondents reported a mean score of 2.21,
standard deviation ±1.09. Registered GPs reported
slightly greater familiarity than GP trainees (mean 2.23
vs 2.17) but this difference was not statistically signifi-
cant. GPs/GP trainees who reported having at least one
MGUS patient within their practice reported greater famil-
iarity with MGUS compared to those that did not report
any patients or selected ‘Prefer not to say’ (2.83 ± 0.99 vs
1.54 ± 0.74; p-value≤0.001). The highest mean familiarity
score was observed for those GP’s/trainees who reported
having 11–50 MGUS patients within their practices (3.4 ±
1.14) although this finding was based on n = 5 participants.
While there were no significant differences between world
regions, respondents from Europe reported being more
familiar with MGUS [mean score (2.26 ± 1.11)] compared
to respondents from Asia (2 ± 1.26), the Americas (1.67 ±
0.58), and Africa (n = 1 participant; data not reported to
maintain confidentiality).
While just over half (53.5%) of the respondents recog-
nised MGUS as being a pre-malignant blood disorder
associated with production of monoclonal protein, only
25.9% (n = 15) of respondents correctly identified MGUS
using the International Myeloma Working Group’s
definition (serum monoclonal protein < 30 g/L, clonal
plasma cells < 10% and absence of end organ damage as-
sociated with the underlying plasma cell disorder, Fig. 1).
GPs/GP trainees with at least one MGUS patient were
more likely to answer correctly compared to respondents
who reported having no MGUS patients (or prefer not to
say) [n = 12 (40%) vs n = 3 (10.7%); p-value = 0.006]. GPs/
GP trainees without experience of MGUS patients (or
who answered ‘prefer not to say) were more likely to re-
port their answer as ‘Don’t know’ compared to respon-
dents with MGUS patients [n = 16 (57.1%) vs n = 6 (20%)].
The majority of participants reported MGUS to be a rare
blood disorder (n = 33; 56.9%) occurring in those aged 50
years and older (n = 29; 50%), Fig. 1. Of the 58 participants,
62.1% (n = 36) correctly identified that MGUS is associated
with an increased risk of malignancy. GPs/GP trainees with
at least one MGUS patient were more likely to answer
correctly (n = 23; 76.7%) compared to respondents who
reported having no experience with MGUS patients or pre-
fer not to say (n = 13; 46.4%; p-value = 0.02). The respon-
dents most commonly associated MGUS with progression
to MM (n = 29/36 respondents; 80.6%), myelodysplastic
syndromes (n = 14; 38.9%) and lymphoma (n = 12; 33.3%).
Of the 40 GPs/trainees who responded to the question on
Fig. 1 Awareness and knowledge of MGUS among GP/GP trainee respondents. Percentages are based on responses from 58 GP/GP trainees
unless otherwise stated by the numbers in brackets. *respondents were allowed to select more than one option and so percentages may not
add up to 100%. Abbreviations: LPL/WM: lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia
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signs and symptoms, 57.5% (n = 23) reported being aware
of signs/symptoms associated with progression. Of the 19
respondents who provided additional detail to this question,
the most frequent signs/symptoms associated with progres-
sion were reported to be bone pain/lesions/osteoporosis
(n = 10; 52.6%), renal disease/abnormalities (n = 7; 36.8%),
infections (n = 5; 26.3%), fever (n = 4; 21.1%), anaemia
(n = 3; 15.8%), bleeding (n = 3; 15.8%), weight loss (n = 3;
15.8%), fatigue (n = 2; 10.5%), weakness (n = 2; 10.5%), in-
crease in M protein/worsening of blood tests (n = 2; 10.5%),
night sweats (n = 1; 5.3%), and hypercalcaemia (n = 1; 5.3%).
MGUS follow-up
Of the 51 participants who completed questions on
MGUS follow-up, 88.2% (n = 45) stated that based on
their current level of knowledge they would not feel
comfortable discussing MGUS with a newly diagnosed
patient, Fig. 1. This finding did not differ by the number
of MGUS patients within the GP practice, however GP
trainees were more likely to report feeling uncomfortable
(n = 19; 100%) compared to practising GP’s (n = 26; 81.3%;
p-value = 0.04). Of the 15 respondents who provided
additional information, 11 (73.3%) stated that they were
uncomfortable due to their limited knowledge/experience
of MGUS and would need to update their knowledge be-
fore advising patients. While the majority of GPs/GP
trainees reported providing information leaflets to some
or all of their patients in general (i.e. any medical diagno-
sis), only 11.8% (n = 6) were aware of the existence of
MGUS information leaflets, Fig. 1.
Of the 58 participants, 46 (79.3%) stated that they
would either refer all or some patients to haematology if
a paraprotein (irrespective of size/isotype) was identified,
Fig. 2. Of the 17 respondents who provided additional
information, reasons for referral included for diagnostic
confirmation and for ruling out malignancy. Some respon-
dents (n = 5) stated they would refer patients due to their
limited knowledge of MGUS, with one GP stating “Inter-
preting monoclonal antibodies is more specialised and
would be outside a GPs competence to interpret these.”
While the majority (n = 21/48 respondents; 43.8%)
deemed haematologists to be the most effective health-
care professionals at following-up MGUS patients, 23%
(n = 11) reported a combination approach consisting of
haematologists, GPs and nurses as the best strategy. Of the
49 respondents who completed questions regarding
follow-up, 40 (81.6%) were happy for (all or some) MGUS
patients to be followed-up via a telephone clinic with a
haematology nurse/haematologist while just 27.1% (n = 13/
48 respondents) stating that they would be happy to
follow-up all low/low-intermediate risk MGUS patients
within their own GP practice, Fig. 2. Respondents
highlighted the need for clear guidelines and guidance from
haematology in order to facilitate follow-up. Additional is-
sues highlighted included GP workload and patient safety,
for example missing follow up or progression to cancer.
When asked, “What services/information should be
provided to GPs/Family Physicians to help them manage
MGUS patients?”, 53.1% (n = 26/49 respondents) of
GPs/GP trainees considered laboratory reports alerting
Fig. 2 GP/GP trainees views towards MGUS follow-up, percentages are based on responses from 58 GP/GP trainees unless otherwise stated by
the numbers in brackets. *respondents were allowed to select more than one option and so percentages may not add up to 100
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them to the possibility of MGUS or a haematological
malignancy as being the most useful service which could
be implemented, Fig. 2. Other additional services which
ranked highly included, information leaflets (38.8%; n =
19), and/or receiving a phone call (34.7%; n = 17) from the
haematology team at the point of patient diagnosis, and/
or an alert by the clinical software system (30.6%; n = 15).
Of the 26 respondents who provided additional informa-
tion, n = 15 (57.7%) highlighted the need for information
and education resources in the form of information leaf-
lets, journal articles, seminars, webinars, courses and a
haematology run website. Respondents were particularly
interested in learning more about diagnosis, risk assess-
ment, follow-up, management and signs/symptoms con-
sidered red flags. An additional n = 6 respondents (23.1%)
highlighted their preference for having direct access to a
haematology specialist or helpdesk when necessary.
Discussion
MM is a rare diagnosis within primary care; the average
GP in the United Kingdom (UK) seeing one new MM
patient every 8–10 years [16]. It is perhaps not surprising
that our survey revealed a low level of knowledge and
awareness of MGUS, the MM precursor among GPs/
trainees. These findings are also in agreement with our
previous studies with MGUS patients and haematology
healthcare professionals which reported low awareness
of MGUS outside of haematology [14]. Despite this,
there is increasing government and public demand for
primary care to expand its role in cancer prevention,
early detection and control, and management within the
community [16]. The challenge therefore remains to in-
crease GP awareness and knowledge of MM and its
precursor MGUS.
Of the 24 most common cancer sites, MM has previ-
ously been associated with the highest percentage of pa-
tients visiting their GP three or more times prior to
diagnosis [17]. Within the UK, 37% of MM cases are still
diagnosed within emergency care and have been reported
to experience poorer outcomes compared to those pa-
tients recognised and referred to secondary care by their
GPs (one-year survival for GP referral vs emergency pres-
entation: 81% vs 51% respectively) [18]. Classified as a
‘hard to suspect’ cancer [19], MM patients typically
present with a myriad of symptoms of a non-specific na-
ture, including, bone pain and extreme fatigue [20]. While
just under 60% of GP’s/trainees in this study reported
knowing the sign/symptoms associated with MGUS pro-
gression, a number of GP’s/trainees respondents stated
that this area was outside of their expertise and that they
would feel uncomfortable discussing the MGUS diagnosis
with their patient. The pathway to cancer diagnosis, relies
on a relationship of trust between the patient and the doc-
tor. The patient must first be aware of the signs/symptoms
to look out for, present to their doctor and their doctor
must recognise the possibility of cancer. This relationship
is more complex within the UK and similar healthcare
systems, where the GP is the gate-keeper to secondary
care and specialist treatment. While GPs are not expected
to be experts in the field, limited knowledge can lead to
delayed identification and negatively impact their patients
[17]. Howell and colleagues (2015) previously reported
blood cancer patients who did not believe their symp-
tom(s) to be serious were more likely to delay presenting
to their doctor [21].
While a ‘watch and wait’ system is currently recom-
mended for MGUS and smouldering MM patients, recent
evidence suggests that initiating treatment early in the
MM pathway may have beneficial effects [22]. Further-
more, in a recent Swedish study, MM patients with a prior
knowledge of MGUS were reported to have better overall
survival compared to patients without a prior MGUS
diagnosis [23]. While not possible to establish a causal link
between follow-up and survival benefits from this single
study, the authors suggest that the findings highlight the
importance of clinical follow-up for all MGUS patients, ir-
respective of risk stratification. However, as a reasonably
common phenomenon detected within older populations
[5], the number of individuals diagnosed with MGUS is
placing an increasing burden on secondary care haematol-
ogy services. Our recent survey of haematologists in the
UK and Irish healthcare systems supported a combined
primary and secondary care effort to manage MGUS pa-
tient follow-up. The findings from the present study sug-
gests that while this approach would have support from
GPs/GP trainees, just over a quarter of respondents were
happy to follow-up all low/low-intermediate risk MGUS
patients within their GP practice. Within several areas in
the UK, outreach haematology monitoring services have
been set up for conditions including MGUS and have
been reported to improve patient satisfaction and reduce
the burden on secondary care [24]. Compliance by general
practice for this service has been reported to be very high
[24]. This survey highlights an opportunity for haematol-
ogy specialists to assist GPs’ in managing MGUS patients
through the provision of clear follow-up guidelines. In
addition, laboratory reports (highlighting MGUS or a
possible blood malignancy), information leaflets and/or
telephone call by haematology team were ranked as the
most effective means of communicating with primary care
regarding MGUS. Future research including the develop-
ment of working groups involving primary care and
haematology specialists could assist in identifying areas of
misunderstanding and in developing relevant resources.
This study is the first to assess knowledge and aware-
ness of MGUS among GPs/primary care physicians.
While the generalisability of our findings may be limited
by the sample size, we report findings from general
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practitioners/trainees working in 24 countries and across
4 continents’. Furthermore, it is well recognised that
GPs are a difficult group to research owing to their work
time constraints. The online nature of the survey and re-
striction to English speakers may have further impacted
the generalisability of the findings however, the survey
was promoted at a European general practitioner confer-
ence and via social media. Similar responses were re-
ported by all respondents suggesting that the findings
are representative and could be applied to other regions
and healthcare services.
Conclusions
In conclusion, the findings of this study highlight a lack of
knowledge and awareness of MGUS among general prac-
titioners/trainees. These findings are important as the
number of MGUS patients detected continues to increase
and follow-up potentially transitions towards primary
care. Our survey suggests the majority of GPs/trainees are
happy with this transition but require assistance and sup-
port from haematology in providing these services.
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